
Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.
Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Indication: Empagliflozin and linagliptin (Glyxambi)is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
Insight:
Sources:





